Santhera halts trial of DMD drug Puldysa, launches revamp

Santhera Pharmaceuticals Holding AG

06/10/2020 06:18

ZURICH, Oct 6 (Reuters) - Santhera Pharmaceuticals  SANN.S 
has halted a late-stage clinical trial of Puldysa (idebenone) in
patients with Duchenne muscular dystrophy (DMD) after data from
an interim analysis  concluded the study was unlikely to meet
its primary endpoint, the Swiss company said on Tuesday.
    "The company intends to initiate a restructuring plan for
the business with a focus on retaining key functions for
bringing DMD drug candidate vamorolone to patients and execute
on its other pipeline programmes," it added in a statement.
 urn:newsml:reuters.com:*:nNDL2v1Z08

 (Reporting by Michael Shields
Editing by Riham Alkousaa)
 ((Michael.Shields@thomsonreuters.com; +41 41 528 3630; Reuters
Messaging: michael.shields.thomsonreuters.com@reuters.net))